JRM-001
Pediatric Single Ventricle Congenital Heart Disease (Heart Failure)
Phase 2/3Recruiting (NCT02781922)
Key Facts
Indication
Pediatric Single Ventricle Congenital Heart Disease (Heart Failure)
Phase
Phase 2/3
Status
Recruiting (NCT02781922)
Company
About Metcela
Metcela develops autologous cardiac stem cell therapies for pediatric heart failure and rare diseases, starting with congenital single ventricle conditions.
View full company profile